Update on the efficacy and safety of combination ezetimibe plus statin therapy

Bibliography

• Clader JW: The discovery of ezetimibe: a view from outside the receptor. J. Med. Chem. 47(1), 1–9 (2004).
   Google Scholar
• Davis HJ, Halleck M: Ezetimibe mechanism of action update and recent controversies. In: The Year in Lipid Disorders (Volume 2). Toth P (Ed.). Clinical Publishing, NY, USA, 81–96 (2010).
   Google Scholar
• Garcia-Calvo M, Lisnock JM, Bull HG et al.: The target of ezetimibe is Niemann-Pick C1-like 1 (NPC1L1). Proc. Natl Acad. Sci. USA 102(23), 8132–8137 (2005).
   Google Scholar
• ▪ First identification of Niemann-Pick Cl-like 1 as the target of ezetimibe.
   Google Scholar
• Altmann SW, Davis HR, Zhu LJ et al.: Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 303(5661), 1201–1204 (2004).
   Google Scholar
• Davis HR, Zhu LJ, Hoos LM et al. Niemann-Pick C1 like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J. Biol. Chem. 279(32), 33586–33592 (2004).
   Google Scholar
• Temel RE, Tang WQ, Ma YY et al.: Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J. Clin. Invest. 117(7), 1968–1978 (2007).
   Google Scholar
• Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB: Ezetimibe – a review of its metabolism, pharmacokinetics and drug interactions. Clin. Pharmacokinet. 44(5), 467–494 (2005).
   Google Scholar
• Hawes BE, O'Neill KA, Yao XR et al.: In vivo responsiveness to ezetimibe correlates with Niemann-Pick C1 like-1 (NPC1L1) binding affinity: comparison of multiple species NPC1L1 orthologs. Mol. Pharmacol. 71(1), 19–29 (2007).
   Google Scholar
• Van Heek M, Farley C, Compton DS et al.: Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br. J. Pharmacol. 129(8), 1748–1754 (2000).
   Google Scholar
• Weinglass AB, Kohler M, Schulte U et al.: Extracellular loop C of NPC1L1 is important for binding to ezetimibe. Proc. Natl Acad. Sci. USA 105(32), 11140–11145 (2008).
   Google Scholar
• Davis HR , Altmann SW: Niemann-Pick C1 like 1 (NPC1L1) an intestinal sterol transporter. Biochim. Biophys. Acta. 1791(7), 679–683 (2009).
   Google Scholar
• Cohen JC, Pertsemlidis A, Fahmi S et al.: Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc. Natl Acad. Sci. USA 103(6), 1810–1815 (2006).
   Google Scholar
• Fahmi S, Yang C, Esmail S, Hobbs HH, Cohen JC: Functional characterization of genetic variants in NPC1L1 supports the sequencing extremes strategy to identify complex trait genes. Hum. Mol. Genet. 17(14), 2101–2107 (2008).
   Google Scholar
• Huff MW, Pollex RL, Hegele RA: NPC1L1: evolution from pharmacological target to physiological sterol transporter. Arterioscler. Thromb. Vasc. Biol. 26(11), 2433–2438 (2006).
   Google Scholar
• Pisciotta L, Fasano T, Bellocchio A et al.: Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. Atherosclerosis 194, E116-E122 (2007).
   Google Scholar
• Simon JS, Karnoub MC, Devlin DJ et al.: Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics 86(6), 648–656 (2005).
   Google Scholar
• Halleck M, Davis HR, Kirschmeier P et al.: An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach. Toxicology 258(2–3), 116–130 (2009).
   Google Scholar
• ▪ Review summarizing toxicology data from extensive database of ezetimibe nonclinical studies.
   Google Scholar
• Tremblay AJ, Lamarche B, Cohn JS, Hogue JC, Couture P: Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 26(5), 1101–1106 (2006).
   Google Scholar
• Ginsberg HN: Review: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J. Clin. Endocrinol. Metab. 91(2), 383–392 (2006).
   Google Scholar
• Lamon-Fava S, Diffenderfer MR, Barrett PH et al.: Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. J. Lipid Res. 48(8), 1746–1753 (2007).
   Google Scholar
• Miettinen TA, Gylling H: Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment. Eur. J. Clin. Invest. 33(11), 976–982 (2003).
   Google Scholar
• Toth PP, Davidson MH: Cholesterol absorption blockade with ezetimibe. Curr. Drug Targets Cardiovasc. Haematol. Disord. 5(6), 455–462 (2005).
   Google Scholar
• Toth PP, Davidson MH: Simvastatin plus ezetimibe : combination therapy for the management of dyslipidaemia. Exp. Opin. Pharmacother. 6(1), 131–139 (2005).
   Google Scholar
• Catapano AL: The pharmacologic elegance of inhibiting cholesterol absorption and synthesis while providing a homeostatic balance. Fundam. Clin. Pharmacol. 21, 21–26 (2007).
   Google Scholar
• Telford DE, Sutherland BG, Edwards JY, Andrews JD, Barrett PH, Huff MW: The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. J. Lipid Res. 48(3), 699–708 (2007).
   Google Scholar
• Tremblay AJ, Lamarche B, Hogue JC, Couture P: Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. J. Lipid Res. 50(7), 1463–1471 (2009).
   Google Scholar
• Zetia®, package insert. Merck/Schering-Plough Pharmaceuticals, PA, USA (2009).
   Google Scholar
• Vytorin®, package insert. Merck/Schering-Plough Pharmaceuticals, PA, USA (2009).
   Google Scholar
• Bays HE, Neff D, Tomassini JE, Tershakovec AM: Ezetimibe: cholesterol lowering and beyond. Expert Rev. Cardiovasc. Ther. 6(4), 447–470 (2008).
   Google Scholar
• Gagne C, Bays HE, Weiss SR et al.: Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. 90(10), 1084–1091 (2002).
   Google Scholar
• Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J: A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin. Proc. 80(5), 587–595 (2005).
   Google Scholar
• Masana L, Mata P, Gagne C et al.: Long-term safety and, tolerability profiles and lipid- modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Ctin. Ther. 27(2), 174–184 (2005).
   Google Scholar
• Conard SE, Bays HE, Leiter LA et al.: Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am. J. Cardiol. 102(11), 1489–1494 (2008).
   Google Scholar
• Leiter LA, Bays H, Conard S et al.: Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am. J. Cardiol. 102(11), 1495–1501 (2008).
   Google Scholar
• Farnier M, Averna M, Missault L et at.: Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy – the IN-CROSS study. Int. J. Clin. Prac. 63(4), 547–559 (2009).
   Google Scholar
• Reckless JPD, Henry P, Pomykaj T et al.: Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int. J. Clin. Prac. 62(4), 539–554 (2008).
   Google Scholar
• Davidson MH, Ballantyne CM, Kerzner B et al.: Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int. J. Clin. Pract. 58(8), 746–755 (2004).
   Google Scholar
• Davidson MH, McGarry T, Bettis R et al.: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. 40(12), 2125–2134 (2002).
   Google Scholar
• Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB: Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin. Proc. 79(5), 620–629 (2004).
   Google Scholar
• Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J: Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am. J. Cardiol. 93(12), 1487–1494 (2004).
   Google Scholar
• Sager P, Melani L, Lipka L et al.: Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am. J. Cardiot. 92, 1414–1418 (2003).
   Google Scholar
• Sager PT, Capece R, Lipka L et al.: Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 179(2), 361–367 (2005).
   Google Scholar
• Ballantyne CM, Houri J, Notarbartolo A et al.: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107(19), 2409–2415 (2003).
   Google Scholar
• Bays HE, Ose L, Fraser N et al.: A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Ctin. Ther. 26(11), 1758–1773 (2004).
   Google Scholar
• Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J: Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am. Heart J. 149(3), 464–473 (2005).
   Google Scholar
• Catapano AL, Davidson MH, Ballantyne CM et al.: Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr. Med. Res. Opin. 22(10), 2041–2053 (2006).
   Google Scholar
• Feldman T, Koren M, Insull W Jr et al.: Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am. J. Cardiot. 93(12), 1481–1486 (2004).
   Google Scholar
• Goldberg RB, Guyton JR, Mazzone T et al.: Ezetimibe/simvastatin vs atorvastatin in patients with Type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Ctin. Proc. 81(12), 1579–1588 (2006).
   Google Scholar
• Foody JM, Brown WV, Zieve F et al.: Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and moderately high/ high risk for coronary heart disease (the VYTELD Study). Am. J. Cardiot. DOI: 10.1016/j.amjcard.2010.06/051 (2010) (Epub ahead of print).
   Google Scholar
• Zieve F, Wenger NK, Ben Yehuda O et al.: Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in patients ≥ 65 years of age (from the ZETia in the ELDerly [ZETELD] study). Am. J. Cardiol. 105(5), 656–663 (2010).
   Google Scholar
• Robinson JG, Davidson MH, Shah A et al.: Efficacy and safety of ezetimibe and ezetimibe+statin therapy in patients aged <65, 65–74, and 75 years and older. Aging Health 3(6), 691–705 (2007).
   Google Scholar
• ▪ Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in 13,382 older patients (>65 years of age) using data pooled from 16 clinical trials.
   Google Scholar
• Constance C, Westphal S, Chung N et al.: Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with Type 2 diabetes mellitus. Diab. Obes. Metab. 9(4), 575–584 (2007).
   Google Scholar
• Robinson JG, Ballantyne CM, Grundy SM et al.: Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am. J. Cardiol 103(12), 1694–1702 (2009).
   Google Scholar
• Conard S, Bays H, Leiter LA et al.: Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diab. Obes. Metab. 12(3), 210–218 (2010).
   Google Scholar
• Abate N, Catapano AL, Ballantyne CM et al.: Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: results of two subgroup analyses. J. Clin. Lipidol. 2(2), 91–105 (2008).
   Google Scholar
• Denke M, Pearson T, McBride P, Gazzara RA, Brady WE, Tershakovec AM: Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab. Vasc. Dis. Res. 3(2), 93–102 (2006).
   Google Scholar
• Simons L, Tonkon M, Masana L et al.: Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr. Med. Res. Opin. 20(9), 1437–1445 (2004).
   Google Scholar
• Feldman T, Ose L, Shah A et al.: Efficacy and safety of ezetimibe/simvastatin versus simvastatin monotherapy in hypercholesterolemic patients with metabolic syndrome. Metab. Syndr. Relat. Disord. 5(1), 13–21 (2007).
   Google Scholar
• Davidson MH, Abate N, Ballantyne CM et al.: Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein. J. Clin. Lipidol. 2(6), 436–446 (2008).
   Google Scholar
• Guyton JR, Goldberg RB, Mazzone T et al.: Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in Type 2 diabetes. J. Clin. Lipidol. 2, 19–24 (2008).
   Google Scholar
• Dujovne CA, Ettinger MP, McNeer JF et al.: Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am. J. Cardiol. 90(10), 1092–1097 (2002).
   Google Scholar
• Pearson TA, Mensah GA, Alexander RW et al.: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107(3), 499–511 (2003).
   Google Scholar
• Ridker PM, Danielson E, Fonseca FAH et al.: Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373(9670), 1175–1182 (2009).
   Google Scholar
• Pearson TA, Ballantyne CM, Veltri E et al.: Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am. J. Cardiol. 103(3), 369–374 (2009).
   Google Scholar
• ▪ Effect of ezetimibe monotherapy on high-sensitivity C-reactive protein and LDL-C reductions using pooled clinical trial data.
   Google Scholar
• Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D: Comparison of effects, of ezetimibe/simvastatin versus simvastatin versus Atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am. J. Cardiol. 99(12), 1706–1713 (2007).
   Google Scholar
• ▪ Effect of combination ezetimibe plus simvastatin versus simvastain and atorvastatin alone on high-sensitivity C-reactive protein and LDL-C reductions using data from clinical trials.
   Google Scholar
• Kinlay S: Low-density lipoprotein-dependent and -independent effects of cholesterollowering therapies on C-reactive protein – a meta-analysis. J. Am. Coll. Cardiol. 49(20), 2003–2009 (2007).
   Google Scholar
• Tannock LR, O'Brien KD, Knopp RH et al.: Cholesterol feeding increases C-reactive protein and serum amyloid a levels in lean insulin-sensitive subjects. Circulation 111(23), 3058–3062 (2005).
   Google Scholar
• Ros E: Intestinal absorption of triglyceride and cholesterol. Dietary and pharmacological inhibition to reduce cardiovascular risk. Atherosclerosis 151(2), 357–379 (2000).
   Google Scholar
• Catapano AL: Perspectives on low-density lipoprotein cholesterol goal achievement. Curr. Med. Res. Opin. 25(2), 431–447 (2009).
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J. Am. Coll. Cardiol. 44(3), 720–732 (2004).
   Google Scholar
• Smith SC Jr, Allen J, Blair SN et al.: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113(19), 2363–2372 (2006).
   Google Scholar
• Leiter LA, Bays H, Conard S et al.: Attainment of Canadian and European guidelines' lipid targets with atorvastatin plus ezetimibe vs doubling the dose of atorvastatin. Int. J. Clin. Prac. DOI: 10.1111/j.1742–1241.2010.02530.x (2010) (In press).
   Google Scholar
• Constance C, Ben Yehuda O, Wenger NK et al.: Better efficacy of atorvastatin with ezetimibe vs uptitration of atorvastatin in the elderly: 2006 Canadian and 2007 European guideline target attainment. Can. J. Cardiol. 25(Suppl. SB), (Abstract 608) (2009).
   Google Scholar
• Genest J, McPherson R, Frohlich J et al.: 2009 Canadian Cardiovascular Society/ Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Can. J. Cardiol. 25(10), 567–579 (2009).
   Google Scholar
• Graham I, Atar D, Borch-Johnsen K et al.: European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur. Heart J. 28(19), 2375–2414 (2007).
   Google Scholar
• Constance C, Ben Yehuda O, Wenger NK et al.: Effects of ezetimibe added to atorvastatin versus atorvastatin up-titration on attainment of single and dual levels for LDL-C and non-HDL-C, apo B or hs-CRP in older adults with high CHD risk. J. Clin. Lipidol. 5(3), 224–225 (2010).
   Google Scholar
• Brunzell JD, Davidson M, Furberg CD et al.: Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care31(4), 811–822 (2008).
   Google Scholar
• Weinstock RS, Goldberg RB, Guyton JR et al.: Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, apoB, and hs-CRP in patients with Type 2 diabetes. J. Clin. Lipidol. 2(1), 25–35 (2008).
   Google Scholar
• Ballantyne CM, Grundy SM, Hsueh WA et al.: Attainment of single and dual treatment levels for LDL-C and non-HDL-C, apo B or hs-CRP in patients with metabolic syndrome: ezetimibe/simvastatin versus atorvastatin. Diabetes 58, A174-A174 (2009).
   Google Scholar
• Zieve F, Brown WV, Foody JM et al.: Attainment of dual treatment levels for hsCRP and lipids in older (≥65) patients with CVD risk: ezetimibe/simvastatin vs atorvastatin. J. Clin. Lipidol. 5(3), 222 (2010).
   Google Scholar
• Graham I, Atar D, Borch-Johnsen K et al.: European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. J. Cardiovasc Prev. Rehabil. 14(Suppl. 2), S1-S113 (2007).
   Google Scholar
• Ingelsson E, Schaefer EJ, Contois JH et al.: Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 298(7), 776–785 (2007).
   Google Scholar
• Rosenson RS, Otvos JD, Freedman DS: Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am. J. Cardiol. 90(2), 89–94 (2002).
   Google Scholar
• Carmena R, Duriez P, Fruchart JC: Atherogenic lipoprotein particles in atherosclerosis. Circulation 109(23 Suppl. 1), III2-III7 (2004).
   Google Scholar
• Kulkarni KR: Cholesterol profile measurement by vertical auto profile method. Clin. Lab. Med. 26(4), 787–802 (2006).
   Google Scholar
• Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T: Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Clin. Ther. 29(11), 2419–2432 (2007).
   Google Scholar
• Tomassini JE, Mazzone T, Goldberg RB et al.: Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes and hypercholesterolaemia. Diabetes Obes. Metab. 11(9), 855–864 (2009).
   Google Scholar
• Bays HE, Conard S, Leiter LA et al.: Effect of ezetimibe added to atorvastatin on lipoprotein subclass cholesterol content in patients with higher versus lower triglyceride levels. J. Clin. Lipidol. 3(3), 224–225 (2009).
   Google Scholar
• Bays HE, Conard SE, Leiter L et al.: Are post-treatment low density lipoprotein subclass pattern analyses potentially misleading? J. Am. Coll. Cardiol. 55(10 Suppl. 1), A53 (2010).
   Google Scholar
• Xydakis AM, Guyton JR, Chiou P, Stein JL, Jones PH, Ballantyne CM: Effectiveness and tolerability of Ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am. J. Cardiol. 94(6), 795–797 (2004).
   Google Scholar
• Zema MJ : Add- o n therapy for hypercholesterolemia: a pilot comparison of two gastrointestinally-acting agents in statin-treated patients. J. Clin. Lipidol. 3(2), 119–124 (2009).
   Google Scholar
• Farnier M, Freeman MW, Macdonell G et al.: Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur. Heart J. 26(9), 897–905 (2005).
   Google Scholar
• McKenney JM, Farnier M, Lo KW et al.: Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J. Am. Coll. Cardiol. 47(8), 1584–1587 (2006).
   Google Scholar
• ▪ Describes the long-term (48-week) lipid-altering effect and safety of ezetimibe combined with fenofibrate.
   Google Scholar
• Fazio S, Guyton J, Polis A et al.: Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. Am. J. Cardiol. 105(4), 487–494 (2010).
   Google Scholar
• ▪ Describes the long-term (64-week) study of the lipid-altering efficacy of ezetimibe/simvastatin in combination with extended-release Niaspan®.
   Google Scholar
• Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM: Lipidaltering efficacy and safety of ezetimibe/ simvastatin coadministered with extended- release niacin in patients with type Ila or type Ilb hyperlipidemia. J. Am. Coll. Cardiol. 51(16), 1564–1572 (2008).
   Google Scholar
• Hachem SB , Mooradian AD: Familial dyslipidaemias: an overview of genetics, pathophysiology and management. Drugs 66(15), 1949–1969 (2006).
   Google Scholar
• Gagne C, Gaudet D, Bruckert E: Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105(21), 2469–2475 (2002).
   Google Scholar
• Yamamoto A, Harada-Shiba M, Endo M et al.: The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy. Atherosclerosis 186(1), 126–131 (2006).
   Google Scholar
• Berge KE, Tian H, Graf GA et al.: Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 290(5497), 1771–1775 (2000).
   Google Scholar
• Stanek EJ, Sarawate C, Willey VJ, Charland SL, Cziraky MJ: Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr. Med. Res. Opin. 23(3), 553–563 (2007).
   Google Scholar
• Salen G, von Bergmann K, Lutjohann D et al.: Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 109(8), 966–971 (2004).
   Google Scholar
• Lutjohann D, von Bergmann K, Sirah W et al.: Long-term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2-year, open-label extension study. Int. J. Clin. Prac. 62(10), 1499–1510 (2008).
   Google Scholar
• ▪ Describes a 2-year study of the safety and lipid-modifying effectiveness of ezetimibe in patients with homozygous sitosterolemia.
   Google Scholar
• Salen G, Starc T, Sisk CM, Patel SB: Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis. Gastroenterology 130(6), 1853–1857 (2006).
   Google Scholar
• Kastelein JJP, Akdim F, Stroes ESG et al.: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358(14), 1431–1443 (2008).
   Google Scholar
• Toth PP, Maki K: A commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) trial: Should ezetimibe move to the "back of the line" as a therapy for dyslipidemia? J. Clin. Lipidol. 2(5), 313–317 (2008).
   Google Scholar
• ▪ Commentary on ENHANCE trial results in the context of other carotid intima-media thickening (cIMT) studies.
   Google Scholar
• Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJP, Stalenhoef AFH: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357(9256), 577–581 (2001).
   Google Scholar
• Stein EA: Additional lipid lowering trials using surrogate measurements of atherosclerosis by carotid intima-media thickness: more clarity or confusion? J. Am. Coll. Cardiol. 52(25), 2206–2209 (2008).
   Google Scholar
• ▪ Discusses the role of cIMT as a surrogate measure in light of cIMT trial results.
   Google Scholar
• van Wissen S, Smilde TJ, Trip MD, Stalenhoef AFH, Kastelein JJP: Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am. J. Cardiol. 95(2), 264–266 (2005).
   Google Scholar
• Simon T, Boutouyrie P, Gompel A et al.: Rationale, design and methods of the CASHMERE study. Fundam. Clin. Pharmacol. 18(1), 131–138 (2004).
   Google Scholar
• Kastelein JJ, van Leuven SI, Burgess L et al.: Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 356(16), 1620–1630 (2007).
   Google Scholar
• Fleg JL, Mete M, Howard BV et al.: Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in Type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J. Am. Coll. Cardiol. 52(25), 2198–2205 (2008).
   Google Scholar
• ▪▪ Describes a substudy of the SANDS trial comparing the effect of statins with ezetimibe plus statins on cIMT.
   Google Scholar
• Howard BV, Roman MJ, Devereux RB et al.: Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes – the SANDS randomized trial. JAMA 299(14), 1678–1689 (2008).
   Google Scholar
• Taylor AJ, Villines TC, Stanek EJ et al.: Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. 361(22), 2113–2122 (2009).
   Google Scholar
• ▪▪ ARBITER 6 trial comparison of extended-release Niaspan and ezetimibe on cIMT.
   Google Scholar
• Duivenvoorden R, Vergeer M, Kastelein JJP: Niacin compared with ezetimibe. N. Engl. J. Med. 362(11), 1046–1047 (2010).
   Google Scholar
• Blumenthal RS, Michos ED: The HALTS trial – halting atherosclerosis or halted too early? N. Engl. J .Med. 361(22), 2178–2180 (2009).
   Google Scholar
• ▪ Commentary on ARBITER 6 cIMT trial of ezetimibe and extended-release Niaspan.
   Google Scholar
• Kastelein JJ , Bots ML: Statin therapy with ezetimibe or niacin in high-risk patients. N. Engl. J. Med. 361(22), 2180–2183 (2009).
   Google Scholar
• ?Commentary on ARBITER 6 cIMT trial of ezetimibe and extended-release Niaspan.
   Google Scholar
• Sibley CT, Gottlieb I, Cox C et al.: Comparative effect of statins vs niacin on MRI measured regression of carotid atherosclerosis in a randomized clinical trial: the NIA Plaque study. Circulation 120(18), S376-S376 (2009).
   Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110(23), 3512–3517 (2004).
   Google Scholar
• Rossebo AB, Pedersen TR, Boman K et al.: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. 359(13), 1343–1356 (2008).
   Google Scholar
• ▪▪ The SEAS trial comparing the effect of ezetimibe plus simvastatin on cardiovascular events in aortic stenosis (AS) patients.
   Google Scholar
• Chan KL, Teo K, Dumesnil JG, Ni A, Tam J: Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Circulation 121(2), 306–314 (2010).
   Google Scholar
• Gerdts E, Rossebø AB, Pedersen TR et al.: Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study). Am. J. Cardiol. (2010) (In press).
   Google Scholar
• ▪ Substudy of the SEAS trial, which assesses rates of aortic valve-related event and ischemic cardiovascular event risk reduction on the basis of AS severity.
   Google Scholar
• Holme I, Boman K, Brudi P et al.: Observed and predicted reduction of ischemic cardiovascular events in the simvastatin and ezetimibe in aortic stenosis trial. Am. J. Cardiol. 105(12), 1802–1808 (2010).
   Google Scholar
• ▪ Substudy of the SEAS trial, assessing the relationship between lipid lowering and ischemic cardiovascular event risk reduction by degree of AS severity.
   Google Scholar
• Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366, 1267–1278 (2005).
   Google Scholar
• ▪▪ Largest meta-analysis of statin trials describing the relationship between LDL-C lowering and cardiovascular event reduction.
   Google Scholar
• SHARP Collaborative Group: Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am. Heart J. DOI: 10.1016/j.ahj.2010.08.012 (2010) (Epub ahead of print).
   Google Scholar
• McCullough P, Verrill T: Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve ouceomes in chronic kidney disease. Postgrad. Med. 122(2), 25–34 (2010).
   Google Scholar
• Holdaas H, Fellstrom B, Jardine AG et al.: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361(9374), 2024–2031 (2003).
   Google Scholar
• Fellstrom BC, Jardine AG, Schmieder RE et al.: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360(14), 1395–1407 (2009).
   Google Scholar
• Wanner C, Krane V, Marz W et ai.: Atorvastatin in patients with Type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353(3), 238–248 (2005).
   Google Scholar
• Cannon CP, Guigliano RP, Blazing MA et al.: Design and Rationale of IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndrome. Am. Heart J. 156(5), 826–832 (2008).
   Google Scholar
• Califf R, Lokhnygina Y, Cannon CP et al.: An update on the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am. Heart J. 159(5), 705–709 (2010).
   Google Scholar
• ▪ Update on the ongoing IMPROVE-IT outcomes trial of ezetimibe plus simvastatin therapy.
   Google Scholar
• Wang HH, Portincasa P, Mendez-Sanchez N, Uribe M, Wang DQH: Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology 134(7), 2101–2110 (2008).
   Google Scholar
• Mathur A, Walker JJ, Al Azzawi HH et al.: Ezetimibe ameliorates cholecystosteatosis. Surgery 142(2), 228–233 (2007).
   Google Scholar
• Valasek MA, Repa JJ, Quan G, Dietschy JM, Turley SD: Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in golden syrian hamsters. Am. J. Physiol. Gastrointest. Liver Physiol. 295(4), G813-G822 (2008).
   Google Scholar
• Kashani A, Sallam T, Bheemreddy S, Mann DL, Wang Y, Foody JM: Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am. J. Cardiol. 101(11), 1606–1613 (2008).
   Google Scholar
• Derosa G, D'Angelo A, Franzetti IG et al.: Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. J. Clin. Pharm. Ther. 34(3), 267–276 (2009).
   Google Scholar
• Peto R, Emberson J, Landray M et al.: Analyses of cancer data from three ezetimibe trials. N. Engl. J. Med. 359(13), 1357–1366 (2008).
   Google Scholar
• ▪▪ Meta-analysis of preliminary safety data in the ongoing IMPROVE-IT and SHARP outcomes trials.
   Google Scholar
• Alsheikh-Ali AA, Karas RH: Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: a post-marketing analysis. J. Clin. Lipid. 3(2), 138–142 (2009).
   Google Scholar
• ▪ Large postmarketing analysis of cancer adverse effects filed with the US FDA for statins, ezetimibe and ezetimibe plus simvastatin.
   Google Scholar
• Robinson JG, Smith B, Maheshwari N, Schrott H: Pleiotropic effects of statins: Benefit beyond cholesterol reduction? A meta-regression analysis. J. Am. Coll. Cardiol. 46(10), 1855–1862 (2005).
   Google Scholar
• ▪ Meta-regression analysis of statin trials assessing the degree of cardiovascular risk reduction compared with nonstatin approaches to lipid lowering.
   Google Scholar
• Robinson JG, Schrott H: Statin pleiotropy: a popular concept but clinical significance unclear. Cardiovasc. Drugs Ther. 21(2), 81–83 (2007).
   Google Scholar
• Robinson JG: Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk. Am. J. Cardiol. 101(7), 1009–1015 (2008).
   Google Scholar
• Shaw SM, Fildes JE, Yonan N, Williams SG: Pleiotropic effects and cholesterol-lowering therapy. Cardiology 112(1), 4–12 (2009).
   Google Scholar
• Nakagami H, Osako MK, Takami Y et al.: Vascular protective effects of ezetimibe in ApoE-deficient mice. Atherosclerosis 203(1), 51–58 (2009).
   Google Scholar
• Kuhlencordt PJ, Padmapriya P, Rutzel S et al.: Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient apoE KO mice. Atherosclerosis 202(1), 48–57 (2009).
   Google Scholar
• Maki-Petaja KM, Booth AD, Hall FC et al.: Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J. Am. Coll. Cardiol. 50(9), 852–858 (2007).
   Google Scholar
• Araujo DB, Bertolami MC, Ferreira WP et al.: Pleiotropic effects with equivalent low-density lipoprotein cholesterol reduction: comparative study between simvastatin and simvastatin/ ezetimibe coadministration. J. Cardiovasc. Pharmacol. 55(1), 1–5 (2010).
   Google Scholar
• Settergren M, Bohm F, Ryden L, Pernow J: Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur. Heart J. 29(14), 1753–1760 (2008).
   Google Scholar
• Olijhoek JK, Hajer GR, van der Graaf Y, Dallinga-Thie GM, Visseren FLJ: The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. J. Cardiovasc. Pharmacol. 52(2), 145–150 (2008).
   Google Scholar
• Landmesser U, Bahlmann F, Mueller M et al.: Simvastatin versus ezetimibe – pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111(18), 2356–2363 (2005).
   Google Scholar
• Gounari P, Tousoulis D, Antoniades C et al.: Effects of rosuvastatin and ezetimibe on flow mediated dilation in patients with congestive heart failure: a double-blind, cross-over trial. J. Am. Coll. Cardiol. 51(10), A228-A228 (2008).
   Google Scholar
• Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK: Evidence for statin pleiotropy in humans differential effects of statins and ezetimibe on Rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 119(1), 131–138 (2009).
   Google Scholar
• Ostad MA, Eggeling S, Tschentscher P et al.: Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study. Atherosclerosis 205(1), 227–232 (2009).
   Google Scholar
• Bulut D, Hanefeld C, Bulut-Streich N, Graf C, Mugge A, Spiecker M: Endothelial function in the forearm circulation of patients with the metabolic syndrome effect of different lipid-lowering regimens. Cardiology 104(4), 176–180 (2005).
   Google Scholar
• Fichtlscherer S, Schmidt-Lucke C, Bojunga S et al.: Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur. Heart J. 27(10), 1182–1190 (2006).
   Google Scholar
• Hussein O, Minasian L, Itzkovich Y, Shestatski K, Solomon L, Zidan J: Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. Br. J. Clin. Pharmacol. 65(5), 637–645 (2008).
   Google Scholar
• Piorkowski M, Fischer S, Stellbaum C et al.: Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone – is sufficient cholesterol-lowering enough to inhibit platelets? J. Am. Coll. Cardiol. 49(10), 1035–1042 (2007).
   Google Scholar
• deGoma EM, deGoma RL, Rader DJ: Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol. 51(23), 2199–2211 (2008).
   Google Scholar
• Chung B, Liang P, Doran S, Cho BH, Franklin F: Postprandial chylomicrons: potent vehicles for transporting cholesterol from endogenous LDL+HDL and cell membranes to the liver via LCAT and CETP. J. Lipid Res. 45(7), 1242–1255 (2004).
   Google Scholar
• van der Veen JN, Kruit JK, Havinga R et al.: Reduced cholesterol absorption upon PPAR Ô activation coincides with decreased intestinal expression of NPC1L1. J. Lipid Res. 46(3), 526–534 (2005).
   Google Scholar
• Briand F, Naik SU, Fuki I et al.: Both the peroxisome proliferator-activated receptor Ô agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL- derived cholesterol. Clin. Transl. Sci. 2(2), 127–133 (2009).
   Google Scholar
• Sehayek E, Hazen SL: Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages. Arterioscler. Thromb. Vasc. Biol. 28(7), 1296–1297 (2008).
   Google Scholar
• Sudhop T, Reber M, Tribble D et al.: Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J. Lipid Res. 50(10), 2117–2123 (2009).
   Google Scholar
• Turner S, Hellerstein M, Davidson MH et al.: Ezetimibe treatment stimulates transport of plasma cholesterol into fecal neutral sterols in hyperlipidemic humans. Presented at: Arteriosclerosis, Thrombosis and Vascular Biology 2010 Scientific Session. San Francisco, CA, USA, 8–10 April 2010.
   Google Scholar
• Telford DE, Huff MW: Postprandial hyperlipidemia: cardiovascular implications and treatment options. Can. J. Cardiol. 24, 32C-37C (2008).
   Google Scholar
• Karpe F: Postprandial lipemia – effect of lipid-lowering drugs. Atheroscl. Suppl. 3(1), 41–46 (2002).
   Google Scholar
• Van Heek M, Compton DS, Davis HR: The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur. J. Pharmacol. 415(1), 79–84 (2001).
   Google Scholar
• Masuda D, Nakagawa-Toyama Y, Nakatani K et al.: Ezetimibe improves postprandial hyperlipidaemia in patients with type Ilb hyperlipidaemia. Eur. J. Clin. Invest. 39(8), 689–698 (2009).
   Google Scholar
• Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Visseren FLJ: The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. Atherosclerosis 202(1), 216–224 (2009).
   Google Scholar
• Torres DM, Harrison SA: Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 134(6), 1682–1698 (2008).
   Google Scholar
• Farrell GC, Larter CZ: Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology 43(2), S99-S112 (2006).
   Google Scholar
• Kotronen A, Yki-Jarvinen H: Fatty liver: a novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28(1), 27–38 (2008).
   Google Scholar
• Deushi M, Nomura M, Kawakami A et al.: Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBSLett. 581(29), 5664–5670 (2007).
   Google Scholar
• Beltroy EP, Liu B, Dietschy JM, Turley SD: Lysosomal unesterified cholesterol content correlates with liver cell death in murine Niemann-Pick type C disease. J. Lipid Res. 48(4), 869–881 (2007).
   Google Scholar
• Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA: Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J. Biol. Chem. 280(13), 12710–12720 (2005).
   Google Scholar
• Zheng SQ, Hoos L, Cook J et al.: Ezetimibe improves high fat and cholesterol diet- induced non-alcoholic fatty liver disease in mice. Eur. J. Pharmacol. 584(1), 118–124 (2008).
   Google Scholar
• Assy N, Grozovski M, Bersudsky I, Szvalb S, Hussein O: Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. World J. Gastroenterol. 12(27), 4369–4376 (2006).
   Google Scholar
• Hughes EA, Tracey I, Singhal S, Patel J: Unexpected beneficial effect in the use of ezetimibe in non-alcoholic fatty liver disease. Med. Hypotheses 67(6), 1463–1464 (2006).
   Google Scholar
• Patel JV, Hughes EA: Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo- simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia. Int. J. Clin. Pract. 60(8), 914–921 (2006).
   Google Scholar
• Chan DC, Watts GF, Gan SK, Ooi EM, Barrett PH: Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 33(5), 1134–1139 (2010).
   Google Scholar
• Reckless J, Davies G, Tunceli K, Hu H, Brudi P: Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study. Value Health 13(6), 726–734 (2010).
   Google Scholar